Sublocade Treatment Michigan: Finding Qualified Providers Near You
Sublocade treatment in Michigan offers a once-monthly injectable solution for opioid use disorder that eliminates the need for daily medication management. This long-acting buprenorphine formulation is administered as a subcutaneous injection under the skin of your stomach, thigh, or upper arm. Clinical studies show that extended-release buprenorphine formulations like Sublocade provide higher retention in treatment compared to daily buprenorphine or placebo. You need to identify DEA-licensed physicians and certified addiction medicine specialists who can prescribe and administer this medication to find qualified providers in Michigan. This piece will help you locate Sublocade providers near you and understand eligibility requirements. You’ll also learn how to move through the treatment process, including insurance coverage options available in Michigan.
What Is Sublocade and How Does It Work?
Buprenorphine Extended-Release Injectable
Sublocade received FDA approval in November 2017 as the first subcutaneously administered extended-release buprenorphine medication given once a month. The formulation uses Atrigel technology that dissolves buprenorphine in a biodegradable delivery system. The solution contacts body fluids after injection as a liquid and forms a solid depot containing buprenorphine beneath your skin. Buprenorphine releases from this depot through diffusion and biodegradation over 28 days. The medication has a half-life of 43-60 days and reaches steady-state concentrations after 4-6 injections given each month. Two strengths are available: 100mg in 0.5mL and 300mg in 1.5mL prefilled syringes.
Once-Monthly Subcutaneous Administration
Your healthcare provider administers Sublocade treatment Michigan through injection into the subcutaneous tissue of your abdomen, with alternative sites including the thigh, buttock, or back of the upper arm. The recommended dosing schedule starts with two 300mg injections of 300mg given each month, followed by 100mg maintenance doses each month. Each injection must be separated by at least 26 days. The 300mg dose provides higher steady-state buprenorphine plasma levels around 5-6 ng/mL that some patients need based on their clinical condition. If you tolerate the 100mg maintenance dose but continue using illicit opioids as evidenced by self-reports or positive urine screens, your provider may increase the dose back to 300mg each month.
How Buprenorphine Reduces Cravings and Withdrawal
Buprenorphine functions as a partial agonist at mu-opioid receptors and a weak kappa receptor antagonist. This partial activation relieves withdrawal symptoms and cravings without producing intense euphoria or respiratory depression seen with full opioids. The medication exhibits high-affinity binding to mu-opioid receptors with slow dissociation and results in milder withdrawal symptoms compared to full agonists. Average buprenorphine plasma concentrations of 2-3 ng/mL achieve mu-opioid receptor occupancy of 70% or greater. In a clinical study, 28% of patients receiving Sublocade plus counseling achieved treatment success compared to 2% on placebo plus counseling. More than that, both Sublocade dosage regimens showed superiority over placebo in achieving more illicit opioid-free weeks. Buprenorphine blocks the rewarding effects of other opioids and helps break the addiction cycle.
Finding Qualified Sublocade Providers in Michigan
DEA-Licensed Physicians and Treatment Centers
Sublocade requires a prescription from healthcare providers who hold special Drug Enforcement Agency licensing. As of June 27, 2023, the Medication Access and Training Expansion (MATE) Act requires most licensed prescribers renewing or applying for new controlled substance DEA licenses to complete at least 8 hours of opioid or substance use disorders training. Providers who completed DATA-2000 waiver training or hold board certification in addiction medicine or addiction psychiatry are exceptions. Physicians, nurse practitioners and physician assistants with required legal permissions can prescribe and administer sublocade treatment Michigan.
The Sublocade Provider Locator Tool
The official Sublocade provider locator tool provides a free search function to identify qualified prescribers near you. This tool lists physicians, nurse practitioners and physician assistants who have prescribed Sublocade at least once in the previous two years and agreed to be included in the directory. You can search by ZIP code and select distance parameters that range from 10 to 50 miles. The tool may also identify Additional Sites of Care where you can receive Sublocade administration even if prescribed elsewhere. Participating providers pay no fee for listing. Inclusion imposes no requirements on treatment methods.
Certified Addiction Medicine Specialists in Michigan
Board certified addiction medicine specialists provide detailed opioid use disorder treatment. To name just one example, providers like those at Beyond Primary Care in Ann Arbor hold dual board certification in family medicine and addiction medicine and utilize buprenorphine products including Sublocade. Clinics in areas such as Benton Harbor offer professional Sublocade administration as part of recovery plans that include counseling and therapy.
Questions to Ask Potential Providers
Ask about your provider’s specific experience with Sublocade and opioid use disorder treatment before you start. Ask whether they specialize in addiction medicine or hold extensive experience beyond general practice. Discuss payment options, insurance acceptance and financial responsibilities including fees for missed appointments. Confirm they offer detailed care that combines medication with counseling, support groups or referrals to additional resources.
Eligibility Requirements for Sublocade Treatment
Prior Stabilization on Oral Buprenorphine
Your provider cannot start sublocade treatment Michigan if you have never taken buprenorphine before. You must first undergo stabilization on a transmucosal buprenorphine product delivering 8-24 mg daily for a minimum of 7 days. This stabilization period will give your body tolerance to buprenorphine and reduces the risk of precipitated withdrawal at the time you transition to the injectable form. Providers verify that you have tolerated and adjusted to the oral dose before administering the subcutaneous injection. Some patients receive a small test dose of oral buprenorphine and get monitored for an hour before receiving their first Sublocade injection the same day.
Medical Evaluation and Health History Review
You must inform your healthcare provider about all medical conditions before starting treatment. Specific concerns include breathing difficulties, lung problems, spinal curvature affecting respiration, Addison’s disease, enlarged prostate, urination problems, liver or kidney issues, gallbladder conditions, mental health problems, alcoholism, head injury, and brain problems. Also mention adrenal or thyroid gland disorders. You should not receive Sublocade if you have allergies to buprenorphine or any ingredient in the prefilled syringe, including the biodegradable polymer or N-methyl-2-pyrrolidone solvent. Women of childbearing potential require a negative pregnancy test before enrollment, and all participants must agree to contraception use throughout treatment.
Moderate to Severe Opioid Use Disorder Diagnosis
Sublocade is indicated for moderate to severe opioid use disorder based on DSM-5 criteria. Moderate OUD involves 4-5 symptoms. Severe OUD requires 6 or more symptoms occurring within a 12-month period. These symptoms include taking opioids in larger amounts than intended, unsuccessful efforts to reduce use, excessive time getting or using opioids, and strong cravings. Other signs are failure to fulfill obligations, continued use despite social problems, giving up activities, and hazardous use. Tolerance and withdrawal also indicate the disorder, along with continued use despite physical or psychological problems.
What to Expect During Sublocade Treatment in Michigan
Monthly Injection Appointments at Provider’s Office
Sublocade is never dispensed directly to you and must only be administered by a healthcare professional in a clinical setting. Your provider schedules monthly visits where they prepare and inject the medication subcutaneously in your abdomen, thigh, buttock, or back of the upper arm. You remain at the healthcare setting after each injection so they can monitor you and assess symptoms of worsening withdrawal or sedation. Your provider checks the injection site during periodic assessments and looks for signs of infection or tampering attempts.
Starting Dose vs Maintenance Dose Schedule
Treatment begins with two first 300mg injections. The second injection may be administered as early as one week after the first injection. After these first doses, the recommended maintenance dosage is 100mg monthly. A 300mg maintenance dose may be worth thinking about if you tolerate 100mg but do not demonstrate satisfactory clinical response. Maintenance doses require at least 26 days between injections.
Medication Combined with Counseling and Support Services
Sublocade must be used as part of a complete treatment program that has counseling and psychosocial support. Treatment combining medication and counseling has been shown to work in addressing behaviors and emotions linked to addiction.
Insurance Coverage for Sublocade in Michigan
88% of insured patients have coverage for Sublocade. Almost 90% of patients with Medicaid pay $0.00. 95% of people enrolled in the Sublocade Copay Assistance Program pay $0.00 if they have commercial insurance.
Conclusion
Sublocade treatment in Michigan provides a monthly solution that works for opioid use disorder without daily medication management. Most insured patients receive coverage with minimal costs, which makes this treatment available. You must first stabilize on oral buprenorphine for at least seven days before starting injections. The official locator tool helps you search for qualified DEA-licensed providers and simplifies the process. Sublocade offers a complete path toward sustained recovery from opioid dependence when you combine it with counseling and support services.